Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial

American Journal of Medicine

Volumn 130, Issue 12, 2017, Pages 1388-1396.e6

  Guo, Yutao ^a   Chen, Yundai ^a   Lane, Deirdre A ^b,c   Liu, Lihong ^d   Wang, Yutang ^a   Lip, Gregory Y H ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c AALBORG UNIVERSITY   (Denmark)

^d Meishan City People's Hospital   (China)

Author keywords

Atrial fibrillation; Drug adherence; Mobile health; Patient education

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL DECISION SUPPORT SYSTEM; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MOBILE APPLICATION; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT PARTICIPATION; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; PILOT STUDY; PROCEDURES; PROSPECTIVE STUDY; TELEMEDICINE;

AGED; ATRIAL FIBRILLATION; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; HUMANS; MALE; MOBILE APPLICATIONS; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; PILOT PROJECTS; PROSPECTIVE STUDIES; TELEMEDICINE;

EID: 85028591811     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.07.003     Document Type: Article

References (31)

1. Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129 (2014), 837–847.
2. Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110 (2004), 1042–1046.
3. Heeringa, J., van der Kuip, D.A., Hofman, A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27 (2006), 949–953.
4. Guo, Y., Tian, Y., Wang, H., et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest 147 (2015), 109–119.
5. Schnabel, R.B., Yin, X., Gona, P., et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 386 (2015), 154–162.
6. Cerasuolo, J.O., Montero-Odasso, M., Ibañez, A., et al. Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami. Int J Stroke 12 (2017), 222–228.
7. Guo, Y., Wang, H., Tian, Y., et al. Time trends of aspirin and warfarin use on stroke and bleeding events in Chinese patients with new-onset atrial fibrillation. Chest 148 (2015), 62–72.
8. Huisman, M.V., Rothman, K.J., Paquette, M., et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol 69 (2017), 777–785.
9. Camm, A.J., Accetta, G., Ambrosio, G., et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart 103 (2017), 307–314.
10. Gamra, H., Murin, J., Chiang, C.-E., et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis 107 (2014), 77–87.
11. Raparelli, V., Proietti, M., Cangemi, R., et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 117 (2017), 209–218.
12. Lip, G., Lip, G.Y.H., Freedman, B., et al. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 117 (2017), 1230–1239.
13. Burke, L.E., Ma, J., Azar, K.M., et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation 132 (2015), 1157–1213.
14. Cowie, M.R., Bax, J., Bruining, N., et al. e-Health: a position statement of the European Society of Cardiology. Eur Heart J 37 (2016), 63–66.
15. Hendriks, J.M., Crijns, H.J., Tieleman, R.G., et al. The atrial fibrillation knowledge scale: development, validation and results. Int J Cardiol 168 (2013), 1422–1428.
16. McHorney, C.A., The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 25 (2009), 215–238.
17. Khan, T.I., Kamali, F., Kesteven, P., et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 126 (2004), 557–564.
18. Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 14 (2012), 1385–1413.
19. January, C.T., Wann, L.S., Alpert, J.S., et al., ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130 (2014), 2071–2104.
20. Lip, G.Y., Laroche, C., Popescu, M.I., et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 17 (2015), 1777–1786.
21. Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (2016), 2893–2962.
22. Eckman, M.H., Lip, G.Y., Wise, R.E., et al. Using an atrial fibrillation decision support tool for thromboprophylaxis in atrial fibrillation: effect of sex and age. J Am Geriatr Soc 64 (2016), 1054–1060.
23. Eckman, M.H., Lip, G.Y., Wise, R.E., et al. Impact of an atrial fibrillation decision support tool on thromboprophylaxis for atrial fibrillation. Am Heart J 176 (2016), 17–27.
24. Wang, Y., Bajorek, B., Pilot of a computerised antithrombotic risk assessment tool version 2 (CARATV2.0) for stroke prevention in atrial fibrillation. Cardiol J 24 (2017), 176–187.
25. Karlsson, L.O., Nilsson, S., Charitakis, E., et al. Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): rationale and design of a cluster randomized trial in the primary care setting. Am Heart J 187 (2017), 45–52.
26. Heidbuchel, H., Verhamme, P., Alings, M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
27. Sauter, T.C., Melis, C., Hautz, W.E., et al. Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practice-a survey of Swiss general internal medicine practitioners. Springerplus, 5, 2016, 2030.
28. Lane, D.A., Aguinaga, L., Blomström-Lundqvist, C., et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 17 (2015), 1747–1769.
29. Clarkesmith, D.E., Lip, G.Y.H., Lane, D.A., Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: a qualitative study. Thromb Res 153 (2017), 19–27.
30. Clarkesmith, D.E., Pattison, H.M., Lip, G.Y., et al. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One, 8, 2013, e74037.
31. Steinberg, B.A., Shrader, P., Thomas, L., et al. Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J 189 (2017), 40–47.